1. Home
  2. CYTK vs GKOS Comparison

CYTK vs GKOS Comparison

Compare CYTK & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • GKOS
  • Stock Information
  • Founded
  • CYTK 1997
  • GKOS 1998
  • Country
  • CYTK United States
  • GKOS United States
  • Employees
  • CYTK N/A
  • GKOS N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • GKOS Medical/Dental Instruments
  • Sector
  • CYTK Health Care
  • GKOS Health Care
  • Exchange
  • CYTK Nasdaq
  • GKOS Nasdaq
  • Market Cap
  • CYTK 5.6B
  • GKOS 5.5B
  • IPO Year
  • CYTK 2004
  • GKOS 2015
  • Fundamental
  • Price
  • CYTK $32.43
  • GKOS $100.14
  • Analyst Decision
  • CYTK Buy
  • GKOS Strong Buy
  • Analyst Count
  • CYTK 14
  • GKOS 13
  • Target Price
  • CYTK $70.92
  • GKOS $135.15
  • AVG Volume (30 Days)
  • CYTK 1.3M
  • GKOS 909.8K
  • Earning Date
  • CYTK 08-07-2025
  • GKOS 07-30-2025
  • Dividend Yield
  • CYTK N/A
  • GKOS N/A
  • EPS Growth
  • CYTK N/A
  • GKOS N/A
  • EPS
  • CYTK N/A
  • GKOS N/A
  • Revenue
  • CYTK $19,218,000.00
  • GKOS $404,523,000.00
  • Revenue This Year
  • CYTK $18.02
  • GKOS $27.88
  • Revenue Next Year
  • CYTK $737.32
  • GKOS $27.60
  • P/E Ratio
  • CYTK N/A
  • GKOS N/A
  • Revenue Growth
  • CYTK 412.21
  • GKOS 23.92
  • 52 Week Low
  • CYTK $29.31
  • GKOS $77.10
  • 52 Week High
  • CYTK $61.38
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 46.32
  • GKOS 58.49
  • Support Level
  • CYTK $32.02
  • GKOS $97.54
  • Resistance Level
  • CYTK $34.72
  • GKOS $102.82
  • Average True Range (ATR)
  • CYTK 1.30
  • GKOS 3.51
  • MACD
  • CYTK 0.26
  • GKOS 0.67
  • Stochastic Oscillator
  • CYTK 45.08
  • GKOS 77.52

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: